<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03499379</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 18244</org_study_id>
    <nct_id>NCT03499379</nct_id>
  </id_info>
  <brief_title>Stress Hormones and IUDs</brief_title>
  <official_title>Effect of Initiation of Intrauterine Contraception on Hair Cortisol Concentration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Family Planning</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Determine what kind of side effects women experience in the first year after they start using
      an intrauterine device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out if there is a difference in levels of stress
      hormones in women who use copper or hormonal intrauterine devices (IUDs). This study will
      provide more information on the potential effect of levonorgestrel intrauterine system
      (LNG-IUS) use on an individual's stress response. Ultimately, this study hopes to provide
      data to better counsel women on potential mood effects of the LNG-IUS. From a research and
      clinical management perspective, hair cortisol may provide a tool to evaluate women at risk
      for discontinuation of hormonal contraception due to concern of mood symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in hair cortisol concentration - 6 months</measure>
    <time_frame>Baseline &amp; 6 months post-insertion</time_frame>
    <description>A hair sample of approximately 10 (up to 20) hairs cut close to the scalp 6 months after start of study participation (baseline - IUD insertion) to assess change from baseline to 6 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in hair cortisol concentration - 12 months</measure>
    <time_frame>Baseline &amp; 12 months post-insertion</time_frame>
    <description>A hair sample of approximately 10 (up to 20) hairs cut close to the scalp 12 months after start of study participation (baseline - IUD insertion) to assess change from baseline to 12 months.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">39</enrollment>
  <condition>Contraception</condition>
  <condition>Mood Change</condition>
  <arm_group>
    <arm_group_label>Women initiating use of an intrauterine device</arm_group_label>
    <description>Women obtaining a copper or hormonal intrauterine device for the purpose of contraception.
A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior vertex will be taken at the time of IUD insertion, 6 months post-insertion, and 12 months post-insertion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mirena</intervention_name>
    <description>A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.</description>
    <arm_group_label>Women initiating use of an intrauterine device</arm_group_label>
    <other_name>levonorgestrel intrauterine system</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Paraguard</intervention_name>
    <description>A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.</description>
    <arm_group_label>Women initiating use of an intrauterine device</arm_group_label>
    <other_name>Copper T380A IUD</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A hair sample of approximately 10 (up to 20) hairs cut close to the scalp of the posterior
      vertex.

      Whole blood samples collected at each study visit (approximately 10mL). The serum from those
      samples will tested for hormone levels.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Study participants will be selected from women's health care clinics in the community.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy

          -  Age 18-39 years

          -  Regular menstrual cycles

          -  Getting an IUD for the purpose of contraception

        Exclusion Criteria:

          -  History of mood disorders

          -  BMI less than 18.5 or greater than 35

          -  Chronic medical conditions

          -  Recently pregnant or lactating
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nora Doty, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 17, 2018</study_first_posted>
  <last_update_submitted>January 3, 2020</last_update_submitted>
  <last_update_submitted_qc>January 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Nora Doty, MD</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <keyword>Intrauterine device (IUD)</keyword>
  <keyword>Depression</keyword>
  <keyword>Stress hormones</keyword>
  <keyword>Mood changes</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

